Biohaven Ltd (BHVN)
39.99
+0.67
(+1.70%)
USD |
NYSE |
May 21, 09:54
Biohaven Enterprise Value: 3.188B for May 20, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 20, 2024 | 3.188B |
| May 17, 2024 | 3.016B |
| May 16, 2024 | 3.111B |
| May 15, 2024 | 2.990B |
| May 14, 2024 | 3.005B |
| May 13, 2024 | 2.699B |
| May 10, 2024 | 2.868B |
| May 09, 2024 | 3.368B |
| May 08, 2024 | 3.317B |
| May 07, 2024 | 3.378B |
| May 06, 2024 | 3.353B |
| May 03, 2024 | 3.308B |
| May 02, 2024 | 3.238B |
| May 01, 2024 | 3.263B |
| April 30, 2024 | 3.141B |
| April 29, 2024 | 3.232B |
| April 26, 2024 | 3.156B |
| April 25, 2024 | 3.118B |
| April 24, 2024 | 3.134B |
| April 23, 2024 | 3.212B |
| April 22, 2024 | 3.100B |
| April 19, 2024 | 2.906B |
| April 18, 2024 | 3.166B |
| April 17, 2024 | 3.319B |
| April 16, 2024 | 3.297B |
| Date | Value |
|---|---|
| April 15, 2024 | 3.379B |
| April 12, 2024 | 4.059B |
| April 11, 2024 | 4.092B |
| April 10, 2024 | 3.894B |
| April 09, 2024 | 3.969B |
| April 08, 2024 | 3.922B |
| April 05, 2024 | 4.013B |
| April 04, 2024 | 3.998B |
| April 03, 2024 | 3.993B |
| April 02, 2024 | 3.872B |
| April 01, 2024 | 3.975B |
| March 28, 2024 | 4.084B |
| March 27, 2024 | 4.275B |
| March 26, 2024 | 4.215B |
| March 25, 2024 | 4.128B |
| March 22, 2024 | 4.179B |
| March 21, 2024 | 4.181B |
| March 20, 2024 | 4.466B |
| March 19, 2024 | 4.269B |
| March 18, 2024 | 4.252B |
| March 15, 2024 | 4.279B |
| March 14, 2024 | 4.226B |
| March 13, 2024 | 4.497B |
| March 12, 2024 | 4.402B |
| March 11, 2024 | 4.141B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-15.64M
Minimum
Sep 29 2022
4.497B
Maximum
Mar 13 2024
1.667B
Average
1.072B
Median
Enterprise Value Benchmarks
| Eli Lilly and Co | 768.05B |
| Viking Therapeutics Inc | 6.482B |
| Altimmune Inc | 388.03M |
| Regeneron Pharmaceuticals Inc | 100.25B |
| vTv Therapeutics Inc | 21.57M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -179.50M |
| Total Expenses (Quarterly) | 183.24M |
| EPS Diluted (Quarterly) | -2.20 |
| Earnings Yield | -17.23% |